← Back to Search

Screening Strategies for Coronary Artery Disease in Kidney Transplant Candidates (CARSK Trial)

N/A
Recruiting
Led By Jagbir Gill, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the analysis will take place at the end of the study. this outcome will be followed up for 5 years.
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if eliminating regular use of non-invasive screening tests for CAD after waitlist activation is not worse than regular screening during wait-listing.

Who is the study for?
This trial is for adults over 18 with dialysis-dependent kidney failure who are being assessed for or on the waiting list for a kidney transplant. They must need further heart disease screening and expect to undergo transplantation more than a year after joining the study. Those with other organ transplants, uncontrolled cardiac issues, or unable to consent are excluded.
What is being tested?
The CARSK trial is examining if not regularly using non-invasive tests to check for coronary artery disease in kidney transplant candidates is as effective as annual screenings in preventing major heart problems. It also looks at how screening affects transplant rates and its cost-effectiveness.
What are the potential side effects?
Since this trial involves no direct medical interventions but compares different frequencies of screening procedures, there are no side effects associated with medications or treatments. However, potential risks may include those related to undergoing diagnostic procedures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the analysis will take place at the end of the study. this outcome will be followed up for 5 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the analysis will take place at the end of the study. this outcome will be followed up for 5 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MACE
Secondary study objectives
All-cause death
Cancellation of transplantation due to coronary artery disease
Cardiovascular death
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: No screeningExperimental Treatment1 Intervention
No further screening for asymptomatic coronary artery disease after wait-list entry
Group II: Regular screeningActive Control1 Intervention
Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,482,150 Total Patients Enrolled
University of SydneyOTHER
198 Previous Clinical Trials
332,700 Total Patients Enrolled
Jagbir Gill, MDPrincipal InvestigatorUniversity of British Columbia
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Regular Screening Clinical Trial Eligibility Overview. Trial Name: NCT03674307 — N/A
Kidney Failure Research Study Groups: No screening, Regular screening
Kidney Failure Clinical Trial 2023: Regular Screening Highlights & Side Effects. Trial Name: NCT03674307 — N/A
Regular Screening 2023 Treatment Timeline for Medical Study. Trial Name: NCT03674307 — N/A
~512 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top